Similar to the controversial effects of the WNT/β-Catenin pathway reported in the literature, we observed that the signature genes that are upregulated or downregulated in the presence of constitutively active CTNNB1 were enriched in ER+/HER2- breast cancer patients with incomplete pathological response to taxane-based chemotherapy in GEO datasets (Figures 3A, B). Here, CTNNB1 is linked to breast carcinoma.